Ohnishi K, Saito M, Nomura F, Okuda K, Suzuki N, Ohtsuki T, Goto N, Takashi M
Am J Gastroenterol. 1987 May;82(5):415-8.
The acute effects of histamine H2 receptor antagonist, famotidine, on hepatic hemodynamics were studied in six normal volunteers and eight patients with chronic liver disease, and its chronic effects on peptic ulcer, portal hemodynamics, and hepatic function were studied in 20 patients with chronic liver disease and peptic ulcer (16 with gastric ulcer, four with duodenal ulcer). Infusion of 20 mg famotidine did not reduce hepatic blood flow and portal blood flow in normal subjects, nor did it reduce cardiac output, the gradient between wedged hepatic vein pressure and free hepatic vein pressure, hepatic blood flow, and portal blood flow in patients with chronic liver disease. An oral dose of 20 mg famotidine twice daily for 2 months healed peptic ulcer in 19 of 20 patients (95%) with chronic liver disease and peptic ulcer, without any change in portal blood flow and hepatic function. Thus famotidine does not appear to alter hepatic hemodynamics and hepatic function in normal subjects and patients with chronic liver disease.
在6名正常志愿者和8名慢性肝病患者中研究了组胺H2受体拮抗剂法莫替丁对肝血流动力学的急性影响，并在20名慢性肝病合并消化性溃疡患者（16例胃溃疡，4例十二指肠溃疡）中研究了其对消化性溃疡、门静脉血流动力学和肝功能的慢性影响。静脉输注20 mg法莫替丁并未降低正常受试者的肝血流量和门静脉血流量，也未降低慢性肝病患者的心输出量、肝静脉楔压与游离肝静脉压之间的梯度、肝血流量和门静脉血流量。对20例慢性肝病合并消化性溃疡患者，每日口服20 mg法莫替丁两次，持续2个月，20例中有19例（95%）消化性溃疡愈合，门静脉血流量和肝功能无任何变化。因此，法莫替丁似乎不会改变正常受试者和慢性肝病患者的肝血流动力学和肝功能。
